Loading...
EVO logo

Evotec SENasdaqGS:EVO Rapporto sulle azioni

Cap. di mercato US$1.0b
Prezzo delle azioni
US$2.80
US$3.69
24.2% sottovalutato sconto intrinseco
1Y-32.2%
7D-0.4%
1D
Valore del portafoglio
​
Vista

Evotec SE

Report azionario NasdaqGS:EVO

Capitalizzazione di mercato: US$1.0b

Evotec (EVO) Panoramica del titolo

Evotec SE opera come società di ricerca e sviluppo di farmaci negli Stati Uniti, in Germania, Francia, Regno Unito, Svizzera e a livello internazionale. Maggiori dettagli

EVO analisi fondamentale
Punteggio fiocco di neve
Valutazione5/6
Crescita futura3/6
Prestazioni passate0/6
Salute finanziaria4/6
Dividendi0/6

Premi

Negoziato a 42.4% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 73.37% all'anno

Negoziato a un buon valore rispetto ai pari e al settore

Analisi del rischio

Non sono stati rilevati rischi per EVO dai nostri controlli di rischio.

EVO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di Evotec SE

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Evotec
Prezzi storici delle azioni
Prezzo attuale dell'azione€2.80
Massimo di 52 settimane€4.42
Minimo di 52 settimane€2.31
Beta1.3
Variazione di 1 mese3.70%
Variazione a 3 mesi13.36%
Variazione di 1 anno-32.20%
Variazione a 3 anni-75.98%
Variazione a 5 anni-87.49%
Variazione dall'IPO158.65%

Notizie e aggiornamenti recenti

Recent updates

Seeking Alpha • Jul 23

Evotec: Recovery Seems To Be Beginning

Summary Evotec remains a speculative 'Buy' with a €20/share price target, offering high long-term potential but requiring patience for upside realization. The company is refocusing on core strengths, expanding Evotec Biologics, leveraging AI, and executing cost-saving measures to improve profitability. Despite high leverage and recent revenue declines, strong partnerships, a robust pipeline, and operational improvements support my continued investment thesis. Risks are significant, but Evotec's growth prospects and current valuation justify maintaining my position for potential outsized returns over several years. Read the full article on Seeking Alpha
Seeking Alpha • Dec 29

Evotec: Some Recovery Has Come, But Much More Is Expected

Summary Evotec, a German drug discovery company, has shown strong top-line growth and significant partnerships, but struggles with financial performance and profitability, making it a speculative "Buy". Despite a 20% return since my last article, Evotec's stock remains volatile, with profitability expected around 2025-2026, driven by strong partnerships and strategic initiatives. The company has a solid liquidity position, low debt, and is on track with cost optimizations and strategic reviews, indicating potential for significant upside. I maintain a price target of €20/share ($11/share for the Nasdaq ticker), viewing Evotec as a speculative investment with a risk/reward-adjusted upside. Read the full article on Seeking Alpha
Seeking Alpha • Aug 30

Evotec: Weak Performance, But Long-Term Potential Is There

Summary Evotec's 28% decline is due to negative EBITDA despite solid top-line revenue growth, highlighting the need for patience in speculative investments. The company is restructuring, focusing on biologics and partnerships with BMY and others, aiming for profitability by 2025 or later. Valuation remains tricky; I cut my price target to $11/share due to delayed market recovery and sluggish revenue recognition. Evotec is a speculative "buy" with high potential but significant risks; I recommend holding and watching for now, not buying more. Read the full article on Seeking Alpha
Seeking Alpha • Apr 24

Evotec: Still A Speculative Buy After A Significant Decline

Summary Evotec SE's stock has declined over 30% in a single day, marking a 5-year decline of over 56%. The company's 2023A results met guidance, but the market expected more from the 2024E forecasts. The change in reporting structure and the stepping down of the CEO have also contributed to the decline in share price. I am still saying "Spec BUY", but with care. Read the full article on Seeking Alpha
Seeking Alpha • Oct 17

Amgen joins TIAP, Evotec at innovation hub for forming life science companies

Toronto Innovation Acceleration Partners (TIAP) and Evotec (NASDAQ:EVO) said the two companies expanded their translational BRIDGE partnership LAB150, to include Amgen (NASDAQ:AMGN) as a strategic partner. The expansion goes along with a combined investment of $14M to expedite LAB150 programs for forming new life science companies, Evotec said in a statement on Monday. TIAP and Evotec created LAB150 in 2017 to accelerate Toronto's academic research into market-ready products. Amgen will provide financial support for chosen LAB150 projects and mentorship from its drug discovery and development teams. In addition, Amgen Ventures will evaluate LAB150-derived companies for venture investment, Evotec noted. "Together with Evotec, we look forward to collaborating with Amgen to bring enhanced expertise and capital to LAB150 to enable life science company creation,” said TIAP President and CEO Parimal Nathwani.
Seeking Alpha • Sep 20

Evotec stock dips despite US DoD contract up to $49.9M to develop antibody for plague

Evotec (NASDAQ:EVO) (OTCPK:EVOTF) said the U.S. Department of Defense (DOD) awarded it a contract worth up to $49.9M for the rapid development of monoclonal antibody (mAb)-based drug product prototypes targeting plague. Under the agreement, Evotec's Seattle-based unit Just - Evotec Biologics will develop mAb-based drug product prototype(s) from sequence discovery or evaluation of existing mAbs to completion of phase 1 first-in-human (FIH) trials, the company said in a Sept. 20 press release. To enable rapid development, Just - Evotec will use its data-driven, automated biologics technology platform J.DESIGN and continuous manufacturing at its J.POD Redmond, Washington (U.S.) facility. Evotec will also provide pre-clinical and clinical capabilities for mAb prophylactic approvals. The contract was awarded by the Joint Project Lead for CBRND Enabling Biotechnologies within the DOD's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense in collaboration with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). EVO -5.24% to $9.41 premarket Sept. 20
Seeking Alpha • Aug 25

Evotec to acquire Central Glass Germany to bolster drug substance manufacturing

Evotec (NASDAQ:EVO) (OTCPK:EVOTF) is acquiring Central Glass Germany from Japanese chemical manufacturing company Central Glass Co. to expands its clinical and commercial manufacturing platform for small molecule therapeutics. Germany-based Evotec said in an Aug. 25 press release that the contract was signed on Aug. 24 at a purchase price of €1. Evotec added it intends to invest in the coming years to establish the facility as a European center of excellence for rare disease drug substance manufacturing. Evotec said Central Glass will now operate as Evotec Drug Substance (Germany) GmbH (Evotec DS). Central Glass is located on a pharmaceutical manufacturing campus in Halle/Westphalia and has a team of ~60 chemical manufacturing experts. The transaction is expected to close on Nov. 1, subject to conditions. Evotec noted that earnings accretion is expected to be achieved by 2023/24. EVO +1.11% to $11.87 premarket Aug. 25
Seeking Alpha • Aug 10

Evotec stock falls amid pact with Alpine for commercial process for potential lupus drug ALPN-303

Evotec (NASDAQ:EVO) said its Seattle-based unit Just - Evotec Biologics expanded a multi-year partnership with Alpine Immune Sciences (NASDAQ:ALPN) to develop a commercial process for ALPN-303. Evotec said ALPN-303 is being developed to treat systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases. The contract is a continuation of the companies first-in-human program initiated in 2020 in which Just - Evotec delivered drug substance materials for Alpine's ongoing phase 1 study and anticipated phase 2 studies of ALPN-303. Under the expanded contract, Just - Evotec Biologics will use its data-driven technology platform to develop a commercial manufacturing process for ALPN-303. The program includes upstream and downstream process, analytical method, and formulation development with a view to support commercial manufacturing of ALPN‑303. Commercial process development activities will be undertaken at Just - Evotec Biologics' J.POD biomanufacturing facility in Redmond, Washington. EVO -10.15% to $12.66 premarket Aug. 10
Seeking Alpha • Jul 06

Boehringer, Evotec, bioMérieux form joint venture Aurobac to combat antimicrobial resistance

Boehringer Ingelheim, Evotec (NASDAQ:EVO) (OTCPK:EVOTF) and bioMérieux formed a joint venture called Aurobac Therapeutics SAS to develop antimicrobials and diagnostics to fight Antimicrobial Resistance (AMR). Aurobac, which will develop a new precision medicine approach from diagnosis to cure, was funded with €40M in total with Boehringer Ingelheim investing €30M and Evotec and bioMérieux funding €5M each, according to the companies' July 6 press release. "Our role within the joint venture is to develop and commercialize diagnostic tests, including Companion Diagnostics, which deliver rapid, reliable and actionable results," said bioMérieux Chairman and CEO Alexandre Mérieux. Boehringer's participation in Aurobac is part of a wider pandemic preparedness initiative, which includes a €50M investment in AMR. Boehringer Ingelheim Venture Fund has committed to invest up to €12M in AMR infection companies.

Rendimenti per gli azionisti

EVOUS Life SciencesUS Mercato
7D-0.4%-0.6%0.5%
1Y-32.2%8.0%23.5%

Ritorno vs Industria: EVO ha avuto una performance inferiore rispetto al US Life Sciences che ha registrato un rendimento 8 % nell'ultimo anno.

Rendimento vs Mercato: EVO ha avuto una performance inferiore al mercato US che ha registrato un rendimento 23.5 % nell'ultimo anno.

Volatilità dei prezzi

Is EVO's price volatile compared to industry and market?
EVO volatility
EVO Average Weekly Movement7.9%
Life Sciences Industry Average Movement8.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

Prezzo delle azioni stabile: EVO non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale ( 8% ) di EVO è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
19934,526Christian Wojczewskiwww.evotec.com

Evotec SE opera come società di ricerca e sviluppo di farmaci negli Stati Uniti, in Germania, Francia, Regno Unito, Svizzera e a livello internazionale. Opera in due segmenti, R&S condivisa e Just - Evotec Biologics. L'azienda sta sviluppando prodotti farmaceutici in diverse aree terapeutiche, quali oncologia, autoimmuni, cancro, diabete, insufficienza cardiaca, immunologia, dolore e infiammazione, malattie infettive, renali, epatiche, respiratorie, fibrotiche e metaboliche e malattie rare.

Evotec SE Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Evotec con la sua capitalizzazione di mercato?
EVO statistiche fondamentali
Capitalizzazione di mercatoUS$1.01b
Utili (TTM)-US$224.73m
Ricavi(TTM)US$863.61m
1.2x
Rapporto P/S
-4.5x
Rapporto P/E

EVO è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
EVO Conto economico (TTM)
Ricavi€745.04m
Costo del fatturato€665.62m
Profitto lordo€79.42m
Altre spese€273.29m
Utili-€193.88m

Ultimi utili riportati

Mar 31, 2026

Prossima data di guadagno

Aug 13, 2026

Utile per azione (EPS)-1.09
Margine lordo10.66%
Margine di profitto netto-26.02%
Rapporto debito/patrimonio netto55.4%

Come si è comportato EVO nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/06/15 02:22
Prezzo dell'azione a fine giornata2026/06/15 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Evotec SE è coperta da 23 analisti. 10 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Christian EhmannBerenberg
Michael RyskinBofA Global Research
Peter VerdultCitigroup Inc